Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

14.13 -4.07

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.08

Max

15.11

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+100.41% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	61M 1.2B
Vorheriger Eröffnungskurs	18.2
Vorheriger Schlusskurs	14.13

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Aug. 2026, 23:56 UTC

Robert Half Inc. shares are roughly flat in after-market hours amid mixed market sentiment and ongoing inflation concerns influencing Federal Reserve rate hike expectations.

27. Aug. 2026, 23:56 UTC

Bright Horizons Family Solutions shares declined in after-market trading, despite remaining above their 20-day moving average amid mixed market sentiment and inflation concerns.

27. Aug. 2026, 23:56 UTC

Correlated Moves

Rockwell Automation Inc shares are lower in after-market trading, reflecting broader market sentiment amid inflation data and expectations for a potential Federal Reserve rate hike.

27. Aug. 2026, 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

27. Aug. 2026, 23:56 UTC

Entravision Communications Corp. shares remained roughly flat in after-market hours, with no specific news identified amid mixed market sentiment and inflation concerns.

27. Aug. 2026, 23:56 UTC

Tennant Co. shares are lower in after-market trading, reflecting mixed market sentiment and ongoing inflation concerns influencing investor expectations for a Federal Reserve rate hike.

27. Aug. 2026, 23:56 UTC

News Corp shares declined in after-market trading following Thursday's close, amid mixed market sentiment and inflation concerns ahead of Federal Reserve comments.

27. Aug. 2026, 23:56 UTC

Coursera Inc. shares are lower in after-market hours, with no specific news identified. Market sentiment is mixed amid inflation concerns and Fed policy anticipation.

27. Aug. 2026, 23:56 UTC

WEX Inc shares are lower in after-market hours with no specific news identified. Broader market sentiment is mixed amid ongoing inflation concerns.

27. Aug. 2026, 23:56 UTC

Omnicell Inc. shares are higher in after-market trading, despite lacking specific company news. Recent economic data continues to influence market sentiment.

27. Aug. 2026, 23:56 UTC

CVS Health shares are higher in after-market trading, recovering from an earlier dip. Market sentiment remains mixed amid ongoing inflation pressures in the U.S.

27. Aug. 2026, 23:56 UTC

Shares of Martin Marietta Materials Inc. moved higher in after-market trading, maintaining gains since Thursday's close, though still below its 20-day moving average.

27. Aug. 2026, 23:56 UTC

Correlated Moves

News

Royal Gold shares are higher in after-market trading following CEO Bill Heissenbuttel's upcoming presentation at the Jefferies Global Industrials Conference on September 10.

27. Aug. 2026, 23:56 UTC

Correlated Moves

News

Diamondback Energy has risen in after-market hours following its joint venture for the Solitude Pipeline System, with analysts estimating a fair value of $232.17.

27. Aug. 2026, 23:56 UTC

ETF Constituents

iShares MSCI Brazil ETF declines in after-market trading due to losses from key holdings VALE and PBR.A, despite mixed global equity sentiment.

27. Aug. 2026, 23:56 UTC

Correlated Moves

Digital Realty Trust shares are lower in after-market trading, reflecting broader sector declines amid ongoing inflation concerns and anticipation of guidance from the Fed.

27. Aug. 2026, 23:56 UTC

Coca-Cola Consolidated Inc shares are lower in after-market trading. No specific company news was identified to explain the decline amid mixed market sentiment.

27. Aug. 2026, 23:56 UTC

EUR/DKK trading roughly flat as mixed sentiment persists amid ongoing inflation concerns and expectations for a Federal Reserve rate hike ahead of Jackson Hole.

27. Aug. 2026, 23:52 UTC

Mexican Consumer Confidence Index Set for Release Amid Mixed Market Sentiment and Ongoing Economic Challenges.

27. Aug. 2026, 23:52 UTC

Japan's July unemployment rate drops to 2.4%, beating forecasts and signaling economic resilience despite inflation concerns.

27. Aug. 2026, 23:52 UTC

ADP Employment Change Report on September 2, 2026, Expected to Reveal Slowing Job Growth Amid Economic Uncertainty.

27. Aug. 2026, 23:52 UTC

Anticipation Builds for Fed Chair Kevin Warsh's Keynote at Jackson Hole Symposium Amid Inflation Concerns and Interest Rate Speculations.

27. Aug. 2026, 23:51 UTC

U-Haul Holding Co shares are lower in after-market hours, continuing a seven-session decline amid broader market dynamics and recent economic data on the labor market.

27. Aug. 2026, 23:51 UTC

Transcat Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

27. Aug. 2026, 23:51 UTC

Insperity Inc. shares are lower in after-market trading, reflecting stability amid broader market dynamics with no specific news identified.

27. Aug. 2026, 23:51 UTC

Evertec Inc shares are lower in after-market hours, reflecting broader market trends. Rising Treasury yields and economic data contribute to the downward pressure.

27. Aug. 2026, 23:51 UTC

Science Applications International Corp. shares are higher in after-market hours, continuing an upward trend since Thursday's close and remaining above the 20-day moving average.

27. Aug. 2026, 23:51 UTC

Trinity Industries Inc shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news identified.

27. Aug. 2026, 23:51 UTC

Yelp Inc shares are lower in after-market hours amid broader market declines. Economic data and geopolitical tensions contribute to negative sentiment in equity markets.

27. Aug. 2026, 23:51 UTC

SLM Corp shares are lower in after-market trading amid a broader market decline and rising Treasury yields, reflecting cautious investor sentiment.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

100.41% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 100.41%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.